Monitoring of serum alpha-foetoprotein (AFP) and human chorionic gonadotrophin (fl-HCG), plays a major role in assessing the effects of treatment in patients with metastatic malignant teratomas (Raghavan et al., 1980; Lange, 1982; Newlands et al., 1983) as well as enabling new innovations to be introduced into treatment of patients who present without metastases (Peckham et al., 1983; Oliver et al., 1983b) .
The development of such approaches in the management of patients with seminoma has been restricted because of the lack of a reliable marker of the disease activity. Several studies using polyclonal antisera have detected the presence of substantial amounts of placental alkaline phosphatase (PLAP) in both tumour tissue and serum of seminoma patients (Wahren et al., 1979; Uchida et al., 1981; Lange et al., 1982; Jeppsson et al., 1983; Dass & Bagshawe, 1984; Nustad et al., 1984) . However, the demonstration that smoking can produce false positive reactions (Tonik et al., 1983; Maslow et al., 1983 ) and the increasing evidence (Millan & Stigbrand, 1983; Paiva et al., 1983) of the complexity of the genetic control of alkaline phosphatase expression, has made it difficult to interpret the results of these investigations.
A new approach to overcoming such problems has been the development of monoclonal antibodies (MAB) to PLAP. One of these, ICRF-H17E2, produced by initial immunization with term placental membranes (Travers & Bodmer, 1984; McLaughlin et al., 1984) , reacts with a heat resistant alkaline phosphatase that is more easily inhibitable by phenyl-alanyl-glycyl-glycine than Lleucine, thus, confirming that it recognises term PLAP. However, when compared with another anti-PLAP MAB (H317), H17E2 has additional reactivity with a L-leucine inhibitable PLAP-like alkaline phosphatase which can be extracted from normal testis (McLaughlin et al., 1984) . The monoclonal H17E2 also has been shown to react strongly with the surface membranes of all of a small number of germ cell tumours of the testis (Epenetos et al., 1984) .
It was therefore decided to use an assay based upon immunolocalisation of enzyme activity (ILEA), to evaluate the potential of H17E2 MAB serum assay for monitoring the treatment of patients with germ cell tumours of the testis. This paper reports the initial results of this study.
Materials and methods

Serum samples
These were selected from a bank of preserved (-20°C) specimens that had been collected since 1979 from patients with seminoma and other testicular germ cell tumours. The staging of disease in these patients and their treatment with conventional cis-platinum containing chemotherapy regimens, has been reported elsewhere (Oliver et al., 1980 (Oliver et al., , 1983a . The histological classification of these tumours was according to the system of the British Testicular Tumour Panel (Pugh & Cameron, 1976) . All sera received for PLAP-like AP determinations had, in addition, been assayed for /3-HCG, AFP and hydroxybutyric dehydrogenase (HBD). An assay for the latter enzyme was included with the established markers, because of its close relationship to lactic dehydrogenase which is known to be elevated in patients with testicular tumours. Control sera were from two sources: Red Cross donor samples remaining after routine Australia antigen screening and females from Guernsey in whom smoking history was known.
Monoclonal antibody H17E2 This murine IgG1 antibody was derived from a hybridoma produced after initial immunisation with purified plasma membranes of normal term placenta. It has been characterised (Travers & Bodmer, 1984) -70°C. Figure 2 shows the results of 9 separate assays of the same pregnancy serum over a period of 6 months, with optical absorbance at 405 nm plotted on a log scale against enzymatic activity converted from Sigma Unitsml-l to International Units (iu -1) (see Methods). The variability at a fixed dilution is fairly constant on a logarithmic scale over the range and gives a coefficient of variation (C.V.) in the original units of + 11.0%. However, it will be seen that there are substantial consistent differences between the 9 assays. It would thus be possible to eliminate part of this between-assay variability by using as standards for calibration, stored aliquots from a single dilution series of a large pregnancy serum pool. This would reduce the between-assay variability to a C.V. of + 6.3%.
The background absorbance in these assays averaged 0.07O.D. for wells (n=61) in which PBS was substituted for the test sera. Accordingly twice the background (0.140.D.) was considered to be the practical lower limit of detection of PLAP activity, an O.D. value corresponding to 0.04 iu 1- (Figure 2) .
The results of selected sera from patients were similarly analysed to provide comparable estimates of inter-test variability both on single repeat testing (13 subjects) and serial sample testing during sustained remission (22 subjects; 2-7 samples each). For the blind re-testing figures the estimated C.V. of a single reading (the mean of 2 replicates) was +15.4%, whereas the repeated sample data gave a within-subject C.V. of + 20.0%. Both th*e estimates of variability eliminate consistent differences between the results of successive assays, and so they should be compared with the reference serum assay variability of +6.3%. The larger C.V. of serial readings is most likely a result of genuine physiological changes within an individual from one time to another. Serum PLAP-like AP levels in patients and controls Sera from two-hundred-and-thirteen Red Cross blood donor controls and from 50 patients with established metastatic testicular germ cell tumours were tested. The distribution of serum PLAP-like AP is shown in Figure 3 . There were no significant differences between male and female control sera (Figure 3a) , and the greater proportion (85% and 80% respectively) had assay readings in the range up to 0.2 O.D. The remaining group had a mean value of 0.36 O.D. in the case of the 24 male sera and 0.32 O.D. for the 11 female sera. The smoking habits of these 35 control individuals were ascertained, where possible, by postal questionnaire. This showed that 10 of the 24 male sera, and 7 of the 11 female sera with PLAP-like. AP values >0.20.D., came from smokers. A further 3 male sera and 1 female serum were from ex-smokers but for the rest of the groups (11 males and 3 females) smoking details could not be obtained. Additional evidence for a smoking effect was obtained from a second control group, viz: 53 females from Guernsey, in whom smoking history was known (Figure 4) . The data suggest a progressive mean rise in serum PLAP-like AP with increased smoking. This trend is highly significant (P=0.0001) as determined by a Wilcoxon rank regression test (Cuzick, in press).
In contrast, in the 50 patients with established metastatic disease (Figure 3b) 
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(optical absorbance at 405 nm) seminoma and malignant teratoma (54%) and 7 of the 21 with malignant teratoma (33%). Details of the range of serum PLAP-like AP levels associated with each of these different tumour sub-types examined, are given in Figure 5 . Again by Wilcoxon rank regression test, a significant (P = 0.002) trend was found for the frequency 'of elevated serum PLAP-like AP to be greater in seminoma than in mixed seminoma and malignant teratoma patients, and also in the latter group compared with the combined patients affected with various types of malignant teratoma. Effect of treatment on serum PLAP-like AP levels Table I shows several examples, in the different patient groups studied (Figure 3b , Figure 5) (Table II) . (Damle et al., 1979) , breast (Wada et al., 1979) , gut (Skinner & Whitehead, 1981) and gonad (Wahren et al., 1979; Uchida et al., 1981; Lange et al., 1982; Haije et al., 1979 (Wahren et al., 1979; Uchida et al., 1981; Lange et al., 1982; Jeppsson et al., 1983) , the identity of the particular variant involved remains uncertain. The results from a recent study of normal testis alkaline phosphatase using MABs to PLAP, suggest that the testis expresses a form of alkaline phosphatase which is controlled by a separate genetic locus (Millan & Stigbrand, 1983) . Although this putative testis locus has different alleles to the PLAP locus, cross-reactions of testis type enzymes with some of the anti-PLAP monoclonal reagents can occur (Millan & Stigbrand, 1983) . This enzyme in current parlance is described as testicular placental alkaline phosphatase-like alkaline phosphatase (testicular PLAP-like AP). Recent studies of the reactivity of the MAB H17E2 used for the present serum assays, have demonstrated that it recognizes both testicular PLAP-like AP and PLAP (Travers & Bodmer, 1984; McLaughlin et al., 1984) . Further preliminary analysis suggests that this antibody is monomorphic as it reacts with the products of all the frequent PLAP alleles (Harris, personal communication). However, its full pattern of reactivity with all the alleles of the testicular PLAP-like AP locus still remains to be established.
Despite these caveats, the data presented herein confirm earlier studies using polyclonal antibodybased assays that serum PLAP-like AP is markedly elevated in the majority of patients with metastatic seminoma, and returns to normal after successful treatment (Wahren et al., 1979; Uchida et al., 1981; Lange et al., 1982; Jeppsson et al., 1983; Dass & Bagshawe, 1984; Nustad et al., 1984) . Furthermore, in the present and two similar studies (Horwich et Johnson, 1984; Millan et al., 1982) , H17E2 and Fl 1 monoclonal immunoassay detected a lower incidence of, respectively, 4/9 and 3/6 seminoma patients with raised serum PLAP, although in both these investigations clinical details supporting the existence of metastases were lacking.
Two new observations also have been made in the course of the present serum marker evaluations. First, elevated levels in patients with malignant teratoma occurred more frequently if there was a mixed tumour with both seminoma and teratoma components. Thus, H 17E2 MAB assay may also have potential in estimating the relative proportion of seminoma present in the metastases in these patients. The second observation relates to the failure to detect PLAP-like AP in sera of two patients, who had extensive metastatic malignant teratoma trophoblastic (MTT) and markedly elevated serum human fl-HCG associated with their disease. It is possible that such patients' tumours are showing less than complete placental differentiation, or have failure of secretion of intracellular products. The latter explanation accords with the absence of raised PLAP-like AP in 18 sera (kindly supplied by Professor Bagshawe) from female patients with highly elevated P-HCG due to metastatic choriocarcinoma (Tucker, unpublished) . A failure of secretion rather than expression is also consistent with the reported intracellular detection of a L-phenylalanine and L-leucine inhibitable form of PLAP by the choriocarcinoma line BEWO (Speeg et al., 1977) . Alternatively, the lack of circulating PLAP-like AP could be due to the tendency of MTT to express the products of early gestational trophoblast rather than those which appear predominantly after the first trimester. However, in one of these two MTT patients immunocytochemical staining of the tumour tissue demonstrated a high content of H17E2 reactive PLAP-like AP, even though the serum level of the enzyme was within normal limits (0.18 O.D.; Figure 5 ). Further study of this type of case may help clarify whether real differences do exist between the neoplastic expression and release of PLAP-like AP in seminoma and malignant teratoma.
Another clinically interesting finding is the one patient with metastatic seminoma who had serum AFP of 14,000 ku I1-and expression of AFP by his tumour as determined by immunocytochemical staining. Some investigators have considered the detection of AFP in the serum of patients with metastatic seminoma indicates the appearance of occult teratoma (Lange et al., 1980) . Others have regarded the appearance of this marker as supporting the idea that seminoma is an intermediate pathological state which evolves to either AFP-or HCG-secreting teratoma (Raghavan et al., 1982) . The PLAP-like AP level in the aforementioned seminoma patient with elevated AFP, was the lowest of all the patients with seminoma (0.06 O.D.; Figure 5 ). In addition, in the analysis of the patients with established metastases, there was a suggestion of a negative association of PLAP-like AP and AFP expression (Table II) . These observations may be a reflection of an interaction between the genes controlling expression of these two cellular products, though study of a larger number of these rare AFP-producing seminomas is clearly necessary.
Previous reports (Tonik et al., 1983; Maslow et al., 1983) that smoking is an important contributory factor to raised levels of serum PLAPlike AP, have been substantiated by the present data obtained from patients in remission and both Guernsey and Red Cross Blood donor control populations. A history of smoking clearly limits the use of serum PLAP-like AP determinations to monitor patients with seminoma after treatment. However, serial assay in remission patients, even if they were smokers, was very reproducible so this should still provide a useful adjunct to radiological examinations for follow-up studies. Further investigations of the underlying causes of the increased levels in smokers will be required in order to improve the specificity of the assay and better understand the patho-physiological effects of smoking.
From a practical standpoint, it is important that the high specificity of the MAB HI 7E2 is exploitable in the ILEA assay with an inter-test reproducibility of PLAP-like AP measurements much the same as previously reported for polyclonal antibody ELISA (Mill'an & Stigbrand, 1981) . These ELISA-type assays also compare favourably with radioimmunoassay, where within assay coefficients of variation for replicates of 3-8%, and between repeats of the same sample on different occasions of 8-20%, have been reported (Chard, 1982) .
There are several potential advantages of the MAB based technique over radioimmunoassay, which should remain applicable with its adaptation to other tumour markers. In particular, ILEA assay does not require the special precautions and separation steps necessary for assays using radioactive material. 
